ArticleNPJ Regenerative medicine2025
Reversion of passaged nucleus pulposus cells to notochordal-type cells by FoxA2 upregulation.
Article in NPJ Regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolving Landscape of Regenerative Therapies: Cell-Based and Cell-Free Approaches for Chronic Low Back Pain.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Notochordal cells (NC) have promise as a regenerative therapy for intervertebral disc (IVD) degeneration, but their maintenance in culture remains challenging. The study hypothesis is that nucleus pulposus (NP) cells can undergo reversion to NC-type cells through CRISPR/dCas9 activation of FoxA2. Serial passaging of cells isolated from NP shows loss of FoxA2, Brachyury (T), and Noto expression. Transient FoxA2 overexpression increased the levels of NC biomarkers, keratin, CD24, and SHH in passaged cells. So FoxA2-expressing cells were generated using CRISPR/dCas9-SAM. Analysis showed the presence of some vacuolated cells, elevated NC marker expression of Fox A2, Noto, Brachyury, and keratin and improved in vitro NP tissue formation (determined by quantifying proteoglycan content). TGFβ3 treatment enhanced tissue formation. Injected FoxA2-expressing cells survived and produced NP matrix molecules in an ex vivo bovine IVD injury model. The findings suggest FoxA2-expressing NC-type cells can be generated which may have potential to advance cell-based therapies for disc degeneration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.